Does KPV kill bacteria?

Two in vitro papers from 2000 reported inhibitory effects against one bacterium and one yeast. That is a laboratory observation in two organisms, not a demonstration of antimicrobial activity in any useful sense, and it has not been developed further in the intervening years.

Why would a peptide raise cAMP in a yeast?

Cyclic AMP signalling is ancient and present across kingdoms, including in fungi where it regulates morphological switching such as germ tube formation. A compound that perturbs adenylyl cyclase activity in a yeast is disturbing a real regulatory system - which is a plausible mechanism, though the partial reversal by an adenylyl cyclase inhibitor shows it is not the whole story.

Does the antimicrobial claim depend on PepT1?

No, and that is one reason to treat the two claims separately. PepT1 is a mammalian intestinal transporter. Whatever route these peptides take into a bacterium or a yeast, it is not that one.

Is picomolar activity plausible?

It is what the paper reports and it is unusual - picomolar potency normally implies a high-affinity specific target. It is one of the reasons the finding would be worth replicating with modern methods, and one of the reasons a single 2000 paper is thin ground on which to build a claim.

KPV

A Second Claim, With a Different Mechanism

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

Two papers from 2000 reported antimicrobial activity for alpha-MSH peptides including the KPV fragment, against Staphylococcus aureus and Candida albicans. The proposed mechanism was an increase in microbial cyclic AMP, which is unrelated to the transporter route that explains the anti-inflammatory work.

Key facts

Primary paper: Cutuli M et al., J Leukoc Biol 2000 (PMID 10670585)
Companion review: Catania A et al., Ann N Y Acad Sci 2000 (PMID 11268348)
Organisms tested: Staphylococcus aureus, Candida albicans
Concentration range reported: Broad, including picomolar
Proposed mechanism: Increased cellular cAMP in the microorganism
Mechanistic test used: Dideoxyadenosine, an adenylyl cyclase inhibitor
Effect on neutrophil killing: Enhanced, not reduced
Human evidence: None

What was reported

Cutuli and colleagues tested alpha-MSH peptides against two organisms chosen as representative pathogens: the gram-positive bacterium Staphylococcus aureus and the yeast Candida albicans. The peptides significantly inhibited S. aureus colony formation and reversed the enhancing effect of urokinase on colony formation. Small concentrations reduced both the viability and the germ tube formation of C. albicans. Effects were reported across a broad concentration range including the picomolar. The companion review by Catania and colleagues states the fragment result explicitly: alpha-MSH and its fragment KPV showed inhibitory influences against S. aureus and C. albicans.

The proposed mechanism, and how it was probed

The suggested route was that these peptides raise cyclic AMP inside the microorganism. Two observations support it. Cyclic AMP was significantly increased in peptide-treated yeast, and dideoxyadenosine - a potent inhibitor of adenylyl cyclase, the enzyme that makes cyclic AMP - partly reversed the killing activity. Partly is the operative word: a partial reversal implicates the pathway without establishing that it accounts for the whole effect, and leaves room for something else contributing.

Research material referenced

KPV 10mg — third-party HPLC tested

View — £24.99

Why this is a genuinely separate claim

This is the point most summaries lose. The anti-inflammatory account of KPV runs through PepT1 carrying the tripeptide into a mammalian cell, where it dampens NF-kappaB and MAP kinase signalling. The antimicrobial account runs through raising cyclic AMP inside a bacterium or a yeast. Different organism, different target, different second messenger, different direction - one story is about suppressing a signalling cascade in a host cell, the other about disturbing signalling in a microbe. They are not two faces of one property, and a description that welds them together into a single 'anti-inflammatory and antimicrobial' characteristic is describing something that has not been shown to exist.

The counterintuitive result about neutrophils

There is a standing problem with anti-inflammatory agents: suppressing inflammation tends to reduce the killing of pathogens, which is why immunosuppression and infection travel together. Cutuli and colleagues tested this directly, asking whether alpha-MSH reduced killing of C. albicans and S. aureus by human neutrophils. It did not - killing was enhanced rather than reduced, which the authors attribute to the direct antimicrobial activity of the peptides. That is an interesting result precisely because the expected direction is the opposite one, and it is the part of this work that would matter most if it held up.

How much weight this literature can carry

Not much on its own, and the reasons are structural rather than a criticism of the work. Both papers are from 2000. Both are in vitro. The specific fragment result for KPV is stated most clearly in a conference-proceedings review rather than in a primary experimental report, which is a weaker place for a load-bearing claim to sit. Two organisms is not a spectrum. And there has been no substantial follow-up establishing an antimicrobial application in the twenty-six years since, which for a genuinely promising antimicrobial finding is itself informative.

What is not being claimed

That KPV is an antibiotic, an antifungal, or a treatment for infection of any kind. It is not, it has never been tested as one in a person, and no regulator anywhere has assessed it for anything. This article describes what two papers reported in laboratory organisms. KPV is supplied here as a material for laboratory research only.

Extended research context

The KPV deep dive

Deep dive: two functions in one hormone, and the case for splitting them

Alpha-MSH is a thirteen-residue peptide cleaved from proopiomelanocortin, and it does two things that have almost nothing to do with each other. Its core sequence engages melanocortin receptors on melanocytes and drives melanin synthesis - the activity it is named for. Separately, it carries anti-inflammatory activity that Brzoska and colleagues localised to its C-terminal end, a paper titled 'terminal signal' precisely because the finding was that the signal sits at the terminus rather than in the receptor-binding core. That is an unusually clean functional separation, and it produced two research compounds pulling in opposite directions from one parent. KPV takes the C-terminal three residues and discards the pigmentation activity. Melanotan II does the reverse - a cyclic analogue built around the receptor-binding portion to maximise exactly what KPV was designed to leave behind. Same hormone, opposite halves.

Deep dive: what happens when you shrink a molecule fivefold

Going from alpha-MSH at 1,664.9 Da to KPV at 342.43 Da is not a trim, it is a change of category. A 1,665 Da peptide is firmly a cell-surface ligand - far too large to cross a membrane passively, so whatever it does must begin at a receptor. A 342 Da tripeptide is small enough that intracellular access becomes plausible, which is why KPV's reported mechanism is described in terms of NF-kappaB signalling rather than melanocortin receptor engagement. The consequence is rarely stated: if the fragment acts inside the cell and the parent acts at its surface, then the anti-inflammatory activity of the two is not necessarily the same phenomenon, and read-across between them should run cautiously in both directions. Fragment logic assumes the fragment is the parent minus something. Here it may be the parent minus something plus a different route of access.

Deep dive: the delivery paper is the most informative thing in the literature

Xiao and colleagues published in Molecular Therapy in 2017 on delivering KPV orally using hyaluronic acid-functionalised nanoparticles targeted to inflamed intestinal tissue. Read as a result it is a delivery success. Read as a statement about the compound it is more interesting: nobody builds a targeted nanoparticle carrier for a molecule that already reaches its target. The existence of that work says the free tripeptide's arrival at inflamed tissue was the limiting problem - which follows directly from being 342 Da, highly soluble and rapidly cleared. It is the same signal that CJC-1295's DAC modification carries for growth hormone secretagogues, or that lipidation carries across the whole incretin class: when the engineering effort goes into getting a compound to stay and arrive rather than into making it more active, the pharmacokinetics were the bottleneck.

Research applications

▸Melanocortin fragment structure-activity research
▸NF-kappaB pathway and cytokine production studies in culture
▸Murine models of induced intestinal inflammation
▸Targeted peptide delivery and carrier system development
▸Comparative work on parent hormones and isolated fragments
▸Analytical method development for very short peptides

Handling checklist

✓Verify identity against Lys-Pro-Val, CID 125672, at 342.43 Da
✓Do not search PubChem for 'KPV' - it returns an unrelated organic acid
✓Store lyophilised, cold, dry and dark
✓Use low-binding consumables; a small cationic peptide adsorbs to surfaces
✓Reconstitute gently down the vial wall and swirl, never shake
✓Aliquot into single-use volumes to avoid freeze-thaw cycling
✓Expect no disulfide or oxidation satellites - no cysteine, no methionine

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Searching PubChem for 'KPV' to verify a certificate

Fix: That returns CID 13294447, 2-oxo-5-phenylpentanoic acid at 192.21 Da, an unrelated compound. Search Lys-Pro-Val for CID 125672.

✗ Treating KPV and alpha-MSH findings as interchangeable

Fix: They differ fivefold in mass and the fragment may act intracellularly where the parent cannot. Read across cautiously in both directions.

✗ Assuming a colitis model result speaks to inflammatory bowel disease

Fix: Induced colitis in a mouse is acute and chemical; human IBD is chronic, heterogeneous and immunologically complex.

✗ Expecting to quantify KPV by absorbance at 280 nm

Fix: There is no aromatic residue in the sequence, so there is no usable absorbance there.

✗ Attributing unexplained low recovery to degradation

Fix: KPV is chemically robust - no cysteine, methionine or asparagine. Adsorption to glass and plastic is the more likely cause.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Does KPV kill bacteria?: Two in vitro papers from 2000 reported inhibitory effects against one bacterium and one yeast. That is a laboratory observation in two organisms, not a demonstration of antimicrobial activity in any useful sense, and it has not been developed further in the intervening years.
Why would a peptide raise cAMP in a yeast?: Cyclic AMP signalling is ancient and present across kingdoms, including in fungi where it regulates morphological switching such as germ tube formation. A compound that perturbs adenylyl cyclase activity in a yeast is disturbing a real regulatory system - which is a plausible mechanism, though the partial reversal by an adenylyl cyclase inhibitor shows it is not the whole story.
Does the antimicrobial claim depend on PepT1?: No, and that is one reason to treat the two claims separately. PepT1 is a mammalian intestinal transporter. Whatever route these peptides take into a bacterium or a yeast, it is not that one.
Is picomolar activity plausible?: It is what the paper reports and it is unusual - picomolar potency normally implies a high-affinity specific target. It is one of the reasons the finding would be worth replicating with modern methods, and one of the reasons a single 2000 paper is thin ground on which to build a claim.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum